4//SEC Filing
KAKKIS EMIL D 4
Accession 0000950170-24-141485
CIK 0001515673other
Filed
Dec 30, 7:00 PM ET
Accepted
Dec 31, 2:05 PM ET
Size
5.8 KB
Accession
0000950170-24-141485
Insider Transaction Report
Form 4
KAKKIS EMIL D
DirectorPresident & CEO10% Owner
Transactions
- Sale
Common Stock
2024-12-30$42.23/sh−11,727$495,231→ 2,183,985 total(indirect: By Trust)
Holdings
- 564,605
Common Stock
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.58 to $43.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F2]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Documents
Issuer
Ultragenyx Pharmaceutical Inc.
CIK 0001515673
Entity typeother
Related Parties
1- filerCIK 0001248093
Filing Metadata
- Form type
- 4
- Filed
- Dec 30, 7:00 PM ET
- Accepted
- Dec 31, 2:05 PM ET
- Size
- 5.8 KB